- Q4 Revenue Growth: Total revenue increased 7% year-over-year to $20.4 million, driven by 5% growth in Interventional Glaucoma ($19.7 million) and 100% sequential increase in Interventional Dry Eye ($0.7 million).<br>
- 2026 Revenue Guidance: Full-year revenue projected to reach $82–88 million (6–14% growth), with Interventional Glaucoma at $77–81 million (2–7% growth) and Interventional Dry Eye at $5–7 million (306–425% growth from prior year).<br>
- Operating Margin Stability: Gross margin maintained at 87%, consistent with prior year, reflecting disciplined cost management and pricing strategy.<br>
- Interventional Dry Eye Momentum: TearCare’s CPT code 0563T adoption enabled $0.7 million in Q4 revenue, up from $0.3 million in 2024, with 10.4 million covered lives and 700,000 MGD patients representing significant market potential.<br>
- Strategic Focus on Glaucoma Expansion: 2026 priorities include expanding combo cataract share and underpenetrated stand-alone glaucoma market, with commercial team investments and the upcoming Ultra product launch to drive utilization growth.<br>
Segment Performance
The Interventional Glaucoma segment continues to be the main driver of revenue, with a focus on expanding the combo cataract segment and developing the underpenetrated stand-alone market. The company is making investments in its commercial infrastructure, including market access and commercial teams, to drive growth. As Paul Badawi mentioned, "We're in a much more stable market and reimbursement environment than we saw a year ago." The Interventional Dry Eye segment is showing promising traction, with revenue increasing to $0.7 million in Q4 2025.
Growth Prospects
Sight Sciences is well-positioned for growth in 2026, with a clear strategy to return to double-digit growth while maintaining operational rigor and financial discipline. Analysts estimate revenue growth of 15.4% for next year, which is slightly above the company's guidance. The company's focus on Interventional Glaucoma and Interventional Dry Eye is expected to drive growth.
Valuation
Using the current stock price and the reported EPS, the P/E Ratio is -5.47, indicating that the stock is trading at a premium. The P/S Ratio is 2.71, which is relatively high compared to the industry average. The EV/EBITDA ratio is -4.68, suggesting that the company's enterprise value is not justified by its EBITDA. The company's ROE and ROIC are both negative, indicating that the company is not generating profits.
Outlook
Sight Sciences is cautiously optimistic about its growth prospects, with a focus on executing its commercial strategy and driving adoption of its Interventional Glaucoma and Interventional Dry Eye technologies. The company's guidance for 2026 suggests that it is confident in its ability to drive growth while maintaining financial discipline. As the company continues to execute on its strategy, investors will be watching to see if it can achieve its growth objectives. The upcoming launch of Ultra, the next iteration of OMNI, is expected to drive growth in the Interventional Glaucoma segment.